临床试验雷达

Has had or is currently suffering from other malignant tumors

There are diseases that affect intravenous injection and venous blood collection

Adverse reactions from previous treatments have not recovered to CTCAE v5.0 Grade 1

Received major surgical treatment, significant traumatic injury within 4 weeks prior to the first dose of TQB2210, or exist long-term unhealed wounds or fractures

Subjects who experience any bleeding or bleeding events ≥ CTCAE grade 3 within 4 weeks prior to the first dose of TQB2210

An arterial/venous thrombotic event occurred within 6 months prior to to the first dose of TQB2210

Patients with active viral hepatitis that is poorly controlled

Active syphilis patients requiring treatment

A history of active pulmonary tuberculosis, idiopathic pulmonary fibrosis, institutional pneumonia, drug-induced pneumonitis/radiation pneumonia requiring treatment or active pneumonia with obvious clinical symptoms, interstitial pneumonia requiring treatment

Subjects with any severe and/or uncontrolled illnesses

Individuals who are preparing for or have previously undergone allogeneic bone marrow transplantation or solid organ transplantation

History of hepatic encephalopathy

Suffering from significant cardiovascular disease

Active or uncontrolled severe infections

Patients with renal failure requiring hemodialysis or peritoneal dialysis;

Corneal defects, corneal ulcers, keratitis or keratoconus, history of corneal transplantation, or other known corneal abnormalities that may increase the risk of developing corneal ulcers within 6 months prior to the first treatment or currently present

History of retinal disease or retinal detachment, or increased risk of retinal detachment according to the opinion of an ophthalmologist

Acute ophthalmic diseases that continue to progress within the first 4 weeks of enrollment

Unwilling to avoid using contact lenses during research treatment

History of immunodeficiency, includingHuman Immunodeficiency Virus（HIV） positivity or other acquired or congenital immunodeficiency diseases

There are poorly controlled autoimmune diseases that require the use of immunosuppressants or systemic hormone therapy to achieve immunity Subjects who inhibit the purpose and need to continue using it within 7 days before the first administration

Individuals with epilepsy who require treatment

Poor control of diabetes

Tumor related symptoms and treatment:

1. Received chemotherapy, immunotherapy, small molecule targeted drugs, etc. within 3 weeks before the first administration;
2. Traditional Chinese patent medicines and simple preparations with anti-tumor indications specified in the National Medical Products Administration (NMPA )approved drug directions within 1 week before the first drug use;
3. Imaging (Computed Tomography or Magnetic Resonance Imaging) shows that the tumor has invaded important blood vessels, or the researcher has determined that the tumor is highly likely to invade important blood vessels and cause fatal massive bleeding during subsequent studies;
4. Uncontrolled pleural effusion, pericardial effusion, or moderate to severe ascites that still require repeated drainage;
5. Known to have spinal cord compression, meningeal metastasis/malignant meningitis, accompanied by symptoms of brain metastasis, or symptoms/imaging control time less than 4 weeks. Within 2 weeks before the start of treatment, steroid therapy or dehydration agents are still required;
6. For non-small cell lung cancer subjects known to have meaningful gene mutations such as epidermal growth factor receptor (EGFR) mutations, anaplastic lymphoma kinase (ALK) fusion, ROS Proto-Oncogene 1, Receptor Tyrosine Kinase (ROS) fusion, etc., they should have received corresponding targeted therapy;
7. Subjects with known human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction cancer and breast cancer should have received corresponding anti HER2 treatment;

Known to be allergic to research drug excipient components

Previously received targeted FGFR2b monoclonal antibod therapy

Previously received chemotherapy drugs used in the protocol (limited to subjects receiving combination therapy during the dose escalation phase only)

Individuals who have participated in and used other anti-tumor clinical trial drugs within 4 weeks prior to their first medication.

According to the judgment of the researchers, there are situations that seriously endanger the safety of the subjects or affect their ability to complete the study